GLP-1s and inflammation: what the research shows

Can GLP-1 medications actually reduce inflammation—or is it simply a result of losing weight?

Research into GLP-1 receptor agonists is uncovering an interesting pattern: certain markers associated with systemic inflammation, particularly C-reactive protein (CRP), appear to decrease during GLP-1 treatment.

But that does not mean medications like Ozempic, Wegovy, Mounjaro, and Zepbound should be considered anti-inflammatory medications.

In this pharmacist-led explanation, we break down what the research actually shows, including:

What CRP tells us about inflammation

Evidence from randomized GLP-1 trials

What researchers found in the STEP weight-management trials

Why the SELECT cardiovascular trial is particularly interesting

Whether reduced inflammation can be explained entirely by weight loss

Why CRP, IL-6, and TNF-alpha don't necessarily tell the same story

How inflammation could potentially relate to cardiovascular benefits

Why GLP-1 medications should not be placed in the same category as traditional anti-inflammatory medications

The key distinction: evidence suggests GLP-1-based therapies may improve certain inflammatory markers, especially CRP. Researchers are still working to understand why this happens and how much it contributes to the medications' long-term health benefits.